

PREFERENTIALLY
RECOMMENDED BY ACIP
FOR ADULTS 65+¹

FLUAD[®]
influenza vaccine,
adjuvanted

GIVE ADULTS 65 YEARS AND OLDER

THE ADJUVANT ADVANTAGE^{*1}

^{*1}Preferentially recommended by ACIP
for adults 65+ over non-adjuvanted,
standard-dose influenza vaccines.

ACIP=Advisory Committee on Immunization Practices

INDICATION AND USAGE

FLUAD is a vaccine indicated for active immunization
for the prevention of influenza disease caused by influenza
virus subtypes A and type B contained in the vaccine. FLUAD
is approved for use in adults 65 years of age and older.

This indication is approved under accelerated approval based on the
immune response elicited by FLUAD. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in a
confirmatory trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUAD to anyone with a history of a severe
allergic reaction (e.g., anaphylaxis) to any component of the
vaccine, including egg protein, or to a previous influenza vaccine.

**Please see Important Safety Information throughout and
full US Prescribing Information for FLUAD.**

DESIGNED TO ADDRESS 2 KEY CHALLENGES



WEAKENED IMMUNE SYSTEM

Vaccine effectiveness may be reduced in adults 65+ as a result of a **weakened immune response** to vaccines^{2,3}



STRAIN MISMATCH


Strain mismatch, which occurred in 7 out of 10 flu seasons from 2010-2011 through 2019-2020, **may further reduce vaccine effectiveness**⁴⁻¹⁴

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

Please see Important Safety Information throughout and [full US Prescribing Information](#) for FLUAD.

ADJUVANTED TO BOOST THE IMMUNE RESPONSE¹⁵⁻¹⁸



[Click here](#) to learn how adding MF59® Adjuvant does more than antigen alone.¹⁵⁻¹⁸

FLUAD[®]
influenza vaccine,
adjuvanted

CHOOSE THE ADJUVANT ADVANTAGE FOR YOUR PATIENTS 65+¹

FLUAD[®]
influenza vaccine,
adjuvanted

ACIP Recommended

ACIP preferentially recommended over standard-dose influenza vaccines for adults 65+.¹

Robust Response

FLUAD[®] produced a robust immune response against all vaccine strains in clinical trials and has a demonstrated safety profile.¹⁵

Adjuvant Technology

Adding an adjuvant strengthens, broadens, and lengthens the immune response more than antigen alone.¹⁶⁻¹⁸

Clinically Effective

20+ years of real-world evidence (RWE) in over 59 million patients supports the clinical effectiveness of the only adjuvanted flu vaccine for adults 65+.^{15,19-31}

Contact your CSL Seqirus representative
for more details or order FLUAD on flu360.com.

WARNINGS AND PRECAUTIONS (continued)

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUAD.

Please see Important Safety Information throughout and [full US Prescribing Information](#) for FLUAD.

CPT CODE 90653:

0.5-mL pre-filled syringe
10 syringes per carton



FLUAD® (Influenza Vaccine, Adjuvanted)

INDICATION AND IMPORTANT SAFETY INFORMATION

CSL Seqirus

INDICATION AND USAGE

FLUAD is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in adults 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUAD to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUAD.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD. Procedures should be in place to avoid injury from fainting.

The immune response to FLUAD in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

The most common ($\geq 10\%$) local and systemic adverse reactions in adults 65 years of age and older who received FLUAD were injection site pain (25%), injection site tenderness (21%), myalgia (15%), fatigue (13%) and headache (13%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see the [full US Prescribing Information for FLUAD](#).

For US Healthcare Professional Use Only

flu360, FLUAD, and MF59 are registered trademarks of Seqirus UK Limited or its affiliates. Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA
©2024 Seqirus USA Inc. June 2024 USA-FLUD-24-0023

References: 1. Grohskopf LA, et al. *MMWR Recomm Rep*. 2023;72(2):1-25. 2. CDC. Flu & people 65 years and older. Accessed March 5, 2024. <https://www.cdc.gov/flu/highrisk/65over.htm> 3. Monto AS, et al. *Vaccine*. 2009;27(37):5043-5053. 4. Skowronski DM, et al. *PLoS One*. 2014;9(3):e92153. 5. CDC. *MMWR Morb Mortal Wkly Rep*. 2011;60(21):705-712. 6. Ohmit SE, et al. *Clin Infect Dis*. 2014;58(3):319-327. 7. McLean HQ, et al. *J Infect Dis*. 2015;211(10):1529-1540. 8. Gaglani M, et al. *J Infect Dis*. 2016;213(10):1546-1556. 9. Zimmerman RK, et al. *Clin Infect Dis*. 2016;63(12):1564-1573. 10. Jackson ML, et al. *N Engl J Med*. 2017;377(6):534-543. 11. Rolfes MA, et al. *Clin Infect Dis*. 2019;69(11):1845-1853. 12. Flannery B, et al. *J Infect Dis*. 2020;221(1):8-15. 13. Tenforde MW, et al. *Clin Infect Dis*. 2021;73(11):e4244-e4250. 14. Zost SJ, et al. *Proc Natl Acad Sci USA*. 2017;114(47):12578-12583. 15. FLUAD. Package insert. Seqirus Inc. 16. O'Hagan DT, et al. *Vaccine*. 2012;30(29):4341-4348. 17. O'Hagan DT, et al. *Expert Rev Vaccines*. 2013;12(1):13-30. 18. Banzhoff A, et al. *Influenza Other Respir Viruses*. 2008;2(6):243-249. 19. Izurieta HS, et al. *Clin Infect Dis*. 2021;73(11):e4251-e4259. 20. Izurieta HS, et al. *J Infect Dis*. 2020;222:278-287. 21. Boikos C, et al. *Clin Infect Dis*. 2021;73(5):816-823. 22. Izurieta HS, et al. *J Infect Dis*. 2019;220:1255-1264. 23. Pelton SI, et al. *Vaccines (Basel)*. 2020;8(3):E446. 24. McConeghy KW, et al. *Clin Infect Dis*. 2021;73(11):e4237-e4243. 25. Cocchio S, et al. *Vaccines*. 2020;8(3):344. 26. Van Buynder PG, et al. *Vaccine*. 2013;31(51):6122-6128. 27. Mannino S, et al. *Am J Epidemiol*. 2012;176(6):527-533. 28. Lapi F, et al. *Expert Rev Vaccines*. 2019;18(6):663-670. 29. Pelton SI, et al. *Vaccine*. 2021;39(17):2396-2407. 30. van Aalst R, et al. *Vaccine*. 2020;38(2):372-379. 31. Data on file. Seqirus Inc; 2023.